Boundless Bio, Inc. (BOLD)
NASDAQ: BOLD · Real-Time Price · USD
1.440
-0.030 (-2.04%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Boundless Bio Employees
Boundless Bio had 28 employees as of December 31, 2025. The number of employees decreased by 36 or -56.25% compared to the previous year.
Employees
28
Change (1Y)
-36
Growth (1Y)
-56.25%
Revenue / Employee
n/a
Profits / Employee
-$2,078,464
Market Cap
32.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28 | -36 | -56.25% |
| Dec 31, 2024 | 64 | -8 | -11.11% |
| Dec 31, 2023 | 72 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| IGC Pharma | 70 |
| Evaxion | 46 |
| NextCure | 40 |
| Werewolf Therapeutics | 39 |
| Daré Bioscience | 24 |
| CervoMed | 15 |
| Skye Bioscience | 12 |
BOLD News
- 11 days ago - Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting - GlobeNewsWire
- 6 weeks ago - Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 - GlobeNewsWire
- 6 weeks ago - Boundless Bio Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 7 weeks ago - Boundless Bio to Participate in the Leerink Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Boundless Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts
- 2 months ago - Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway - GlobeNewsWire